Albany, NY -- (SBWIRE) -- 05/08/2018 -- Cellular therapy is also known as cytotherapy or cell therapy. Cellular therapy (CT) is the transplantation of cellular material into human body to repair or replace damaged tissue and damaged cells. Advancement in technology, development of innovative products, and growth in the number of research activities have helped in the discovery of several types of cells that are likely to be used in the treatment or therapy of various conditions and diseases. Several cells such as hematopoietic stem cells (HSC), mesenchymal stem cells, skeletal muscle stem cells, dendritic cells, pancreatic islet cells, and lymphocytes can be used in cellular therapy.
HSC is extensively used in cellular therapy. Cellular therapy is used to treat various types of cancers, infectious diseases, autoimmune diseases, and urinary problems. The therapy also helps patients rebuild damaged cartilage in joints, improve a weakened immune system, and repair spinal cord injuries. Moreover, it also helps treat neurological disorders. Cellular cancer therapy has various approaches as the cell can be designed to stimulate the patient’s immune system (T cells or natural killer cells) to kill cancer cells, or to replace most of the patient’s immune system to enhance their immune response to cancer cells, or to directly find and kill the cancer cells.
The global Cellular Therapy In Oncology Market has been classified based on cancer type and geography. In terms of cancer type, the market has been categorized into blood cancer, prostate cancer, pancreatic cancer, brain cancer, and other cancer. The blood cancer segment accounts for a major share of cellular therapy in oncology market. Increasing prevalence of prostate cancer is expected propel the segment in the near future. According to WHO statistics, 8.2 million people die each year due to cancer which estimates about 13% of all death worldwide. There are more than 100 types of cancers that require unique diagnoses and therapies. This increases the demand for cellular therapy in oncology in near future.
Request to View Brochure of Report -
Geographically, the cellular therapy in oncology market has been segmented into five major regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. In terms of revenue, North America dominates the cellular therapy in oncology market followed by Europe. The market in Asia Pacific and Latin America is developing. This trend is expected to continue during the forecast period. Availability of large patient pool, expansion of the health care industry, and rise in government investment to improve the health care industry are anticipated to propel the market in these regions. The cellular therapy in oncology market in countries such as Brazil, China, and India are projected to expand at substantial growth rate during the forecast period due to rise in awareness among the population about the usage of cellular therapy to treat various types of cancers and rapid innovations in cellular therapy.
Increasing prevalence of various cancers, affordability of cellular therapy in cancer drugs, high adoption in developed markets, and development of innovative drugs are other factors driving the cellular therapy in oncology market. High competition among existing players, high risks of failure, severity and complications involved in cellular therapy due to misdiagnosis, and lack of awareness among the rural population in underdeveloped and developing economies are likely to inhibit the market.
Major players operating in the cellular therapy in oncology market include Alkem Laboratories Limited, Amgen, Inc., Bayer AG, Sanofi, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd, Cipla, Inc., Merck & Co., Inc., Eli Lilly and Company, GlaxoSmithKline Plc., Johnson & Johnson Services, Inc., Novartis AG, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.
Enquiry for discount on this report -